Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
2020; Massachusetts Medical Society; Volume: 382; Issue: 19 Linguagem: Inglês
10.1056/nejmoa1917635
ISSN1533-4406
AutoresRobert Zeiser, Nikolas von Bubnoff, Jason Butler, Mohamad Mohty, Dietger Niederwieser, Reuven Or, Jeff Szer, Eva Wagner, Tsila Zuckerman, Bruyère Mahuzier, Judith Xu, Celine Wilke, Kunal K. Gandhi, Gèrard Socié,
Tópico(s)T-cell and B-cell Immunology
ResumoAcute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.
Referência(s)